May 24, 2017
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) has expanded the indication for the short-acting beta-agonist albuterol sulfate inhalation powder (ProAir RespiClick, Teva) to children aged 4 to 11 years, the company announced today.




Side Effects


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions are shown in Table 3 and are generally related to vasodilatory effects.

Table 3: Adverse Reactions Occurring in Patients with Idiopathic or Heritable PAH and with PAH Associated with Scleroderma Spectrum of Diseases (PAH/SSD) Occurring ≥ 10% More Frequently on FLOLAN than Conventional Therapy

Adverse Reaction Idiopathic or Heritable PAH PAH/SSD
(n = 52)
Conventional Therapy
(n = 54)
(n = 56)
Conventional Therapy
(n = 55)
Body as a whole
Jaw pain 54% 0% 75% 0%
Nonspecific musculoskeletal pain 35% 15% 84% 65%
Headache 83% 33% 46% 5%
Chills/ fever/ sepsis/ flu-like symptoms 25% 11% 13% 11%
Cardiovascular system
Flushing 42% 2% 23% 0%
Hypotension 27% 31% 13% 0%
Tachycardia 35% 24% 43% 42%
Digestive system
Anorexia 25% 30% 66% 47%
Nausea/ Vomiting 67% 48% 41% 16%
Diarrhea 37% 6% 50% 5%
Skin and Appendages
Skin ulcer - - 39% 24%
Eczema/ rash/ urticaria 10% 13% 25% 4%
Musculoskeletal System
Myalgia 44% 31% .- -
Nervous system
Anxiety/ hyperkinesias / nervousness/ tremor 21% 9% 7% 5%
Hyperesthesia/ hypesthesia / paresthesia 12% 2% 5% 0%
Dizziness 83% 70% 59% 76%

Adverse Events Attributable to the Drug Delivery System

Chronic infusions of FLOLAN are delivered using a small, portable infusion pump through an indwelling central venous catheter. During controlled PAH trials of up to 12 weeks' duration, the local infection rate was about 18%, and the rate for pain was about 11%. During long-term follow-up, sepsis was reported at a rate of 0.3 infections/patient per year in patients treated with FLOLAN.

Postmarketing Experience

The following events have been identified during postapproval use of FLOLAN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic

Anemia, hypersplenism, pancytopenia, splenomegaly, thrombocytopenia.

Endocrine and Metabolic



Hepatic failure.

Respiratory, Thoracic, and Mediastinal

Pulmonary embolism.

Read the Flolan (epoprostenol sodium) Side Effects Center for a complete guide to possible side effects


No information provided.

Read the Flolan Drug Interactions Center for a complete guide to possible interactions

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/1/2016

Side Effects

Flolan - User Reviews

Flolan User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Flolan sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.